The SYNERGY II Everolimus elutiNg stent In patients Older than 75 years undergoing coronary Revascularisation associated with a short dual antiplatelet therapy (SENIOR) trial: rationale and design of a large-scale randomised multicentre study

Varenne, Olivier; Cuisset, Thomas; Chaïb, Aurès; Morice, Marie-Claude; Sabaté, Manel; Koh, Tian-Hai; Durand-Zaleski, Isabelle; Hanon, Olivier; Bogaerts, Kris; Sinnaeve, Peter

doi:10.4244/EIJY15M12_02

The SYNERGY II Everolimus elutiNg stent In patients Older than 75 years undergoing coronary Revascularisation associated with a short dual antiplatelet therapy (SENIOR) trial: rationale and design of a large-scale randomised multicentre study

Author:

Varenne, Olivier

Cuisset, Thomas ; Chaïb, Aurès ; Morice, Marie-Claude ; Sabaté, Manel ; Koh, Tian-Hai ; Durand-Zaleski, Isabelle ; Hanon, Olivier ; Bogaerts, Kris ; Sinnaeve, Peter

Keywords:

Science & Technology, Life Sciences & Biomedicine, Cardiac & Cardiovascular Systems, Cardiovascular System & Cardiology, bare metal stent, coronary artery disease, drug-eluting stent, BARE-METAL STENTS, BIODEGRADABLE POLYMER, DURABLE POLYMER, ESC GUIDELINES, IMPLANTATION, INTERVENTION, THROMBOSIS, EFFICACY, LEADERS, SAFETY, Aged, Aged, 80 and over, Drug-Eluting Stents, Female, Humans, Male, Myocardial Infarction, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Prospective Studies, Sirolimus, 0104 Statistics, 3201 Cardiovascular medicine and haematology

Abstract:

In the elderly population, bare metal stents (BMS) are often preferred over drug-eluting stents (DES) because of the longer duration of dual antiplatelet therapy (DAPT) associated with the latter. The SENIOR trial is designed to determine whether one of the latest generation of DES can reduce major cardiovascular events compared to BMS, despite a similar short DAPT duration.